Latest Headlines

  1. J&J’s Ethicon Expands Energy Device Offerings With Megadyne Purchase

    Johnson & Johnson (J&J) subsidiary Ethicon has broadened its suite of electrosurgical devices and accessories with the acquisition of Megadyne for an undisclosed amount. The combined companies expect greater innovation capabilities in the electrosurgical field, and are positioned to market Megadyne’s innovative portfolio to a broader global market.

  2. FDA Launches Oncology Center of Excellence, Appoints Pazdur As Director

    The U.S. Food and Drug Administration (FDA) has officially launched its Oncology Center of Excellence (OCE) to coordinate the clinical review of drugs, biologics, and devices across the agency’s three medical product centers. Dr. Richard Pazdur, FDA's cancer drug director since 2005, will lead OCE.

  3. Philips, Banner Health Ink 15-Year Connected Healthcare Pact

    Royal Philips a leading health technology company, and Arizona-based Banner Health, recently announced a multi-year partnership intended to further innovate and expand on their successful joint connected healthcare programs such as the Intensive Ambulatory Care (IAC) pilot and telehealth programs.

  4. FDA Grants BD’s Pleural Effusion System Gains Expanded Indication

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its PleurX™ catheter system received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use in specific non-malignant  recurrent pleural effusions etiologies, including congestive heart failure, during the 53rd Annual Society of Thoracic Surgeons (STS) Meeting, taking place Jan. 21-25 at the George R. Brown Convention Center in Houston, Texas.

  5. FDA Issues Two Draft Guidances On Medical Product Communications

    The first deals with communication by firms of health care economic information (HCEI) to payors, including about investigational drugs and devices that are not yet approved or cleared for any use. The second pertains to medical product communications that include data and information not contained in product labeling, but concerning the approved or cleared uses of those products.

  6. Blood-Repelling Titanium Surfaces Could Lower Implant Rejection Rates

    Scientists from Colorado State University (CSU) have demonstrated that hemophobic surfaces significantly reduce platelet adhesion and activation, a process that can lead to life-threatening blood clots.

  7. Global Smart Wearables Market Projected To Pass $30B By 2020

    Research and Markets has announced the addition of the "Global Smart Wearables Market and Forecast to 2021" report to their offering.

  8. OssDsign’s 3D-Printed Cranial Implant Cleared By FDA

    Karolinska Development AB (Nasdaq Stockholm: KDEV) notes that portfolio company OssDsign AB, a Swedish designer, manufacturer and distributor of next generation implants for cranial and facial reconstruction, has today announced it has received 510(k) clearance by the US FDA for marketing of OSSDSIGN® Cranial PSI in the USA.

  9. Hitachi Integrates, Expands Healthcare Businesses Serving Americas

    Hitachi, Ltd. recently announced the formation of a new Americas business group focused on consolidating its various medical imaging offerings while expanding its focus on Healthcare Innovation & Informatics. Hitachi will  combine Hitachi Aloka Medical America, Inc. into Hitachi Medical Systems America, Inc. on April 1, 2017, which will then change its name to Hitachi Healthcare America Corporation.

  10. FDA Touts EvGen, IMEDS Programs Ensuring Patient Safety

    The U.S. Food and Drug Administration (FDA) unveiled a website for its National Medical Evidence Generation Collaborative (EvGen), intended to bring wider access to high-quality scientific evidence supporting the safe use of FDA-regulated products.